Preclinical comparison of 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy

Journal of Nuclear Medicine

Volumn 43, Issue 12, 2002, Pages 1650-1656

  Breeman, Wouter A P ^a   De Jong, Marion ^a   Erion, Jack L ^b   Bugaj, Joseph E ^b   Srinivasan, Ananth ^b   Bernard, Bert F ^a   Kwekkeboom, Dik J ^a   Visser, Theo J ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

Bombesin analogs; DOTA; DTPA; Gastrin releasing peptide receptor; Receptor scintigraphy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BOMBESIN; GASTRIN RELEASING PEPTIDE; INDIUM 111; PENTETIC ACID; RADIOISOTOPE; RADIOLIGAND; RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; RECEPTOR BINDING; SCINTIGRAPHY; TEMPERATURE; TIME; TISSUE DISTRIBUTION; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; BOMBESIN; INDIUM RADIOISOTOPES; MALE; MOLECULAR SEQUENCE DATA; PENTETIC ACID; RADIOPHARMACEUTICALS; RATS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 0036898728     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
2. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
3. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer. 2000;88:652-657.
4. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999:81:658-665.
5. 1]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657-663.
6. 123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
7. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
8. Otte A, Jermann E, Behe M, et al. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792-795.
9. Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Antiproliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer. 1999;81:767-771.
10. 111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49:1583-1591.
11. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441.
12. 111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci. 1991;49:1593-1601.
13. 111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med. 1994;21:328-335.
14. de Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368-371.
15. Raynor K, Reisine T. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharmacol Exp Ther. 1989;251:510-517.
16. Visser-Wisselaar HA, Van Uffelen CJ, Van Koetsveld PM, et al. 17-Beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology. 1997;138:1180-1189.
17. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res. 1997;57:659-671.
18. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study. Eur J Nucl Med. 2000;27:1694-1699.
19. Davis TP, Crowell S, Taylor J, et al. Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. Peptides. 1992;13:401-407.
20. Rogers BE, Rosenfeld ME, Khazaeli MB, et al. Localization of iodine-125-mlP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med. 1997;38:1221-1229.
21. Breeman WA, VanHagen MP, Visser-Wisselaar HA, et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med. 1996;37:108-117.
22. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med. 1998;39:1928-1936.
23. Jansen JB, Jebbink MC, Douglas BR, Lamers CB. Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man. Eur J Clin Pharmacol. 1990;38:367-370.